Wound Fluid Biomarker Diagnostics for Refractory Ulcers
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for diabetic foot ulcers (DFUs) lack early objective indicators of wound healing outcomes, leading to delayed adoption of advanced therapies and increased risk of amputation, as standard care methods are often ineffective in refractory wounds.
Innovation Solution
The use of specific biomarkers detected in wound fluid, such as a low cysteine to cystine ratio, to predict non-healing wounds, allowing for early identification and application of advanced therapies like debridement, negative pressure therapies, and surgical procedures.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If standard care therapy is used for diabetic foot ulcers, then treatment simplicity is maintained, but wound healing outcome prediction accuracy deteriorates and treatment timing is delayed
Solution Approach 1:
The patent changes the measurement parameter from traditional clinical wound size assessments to metabolite profile analysis in wound fluid. By detecting specific metabolites (amino acids, carbohydrates, vitamins, nucleotides, xenobiotics, peptides) and their ratios, the system provides objective biomarkers that accurately predict healing outcomes, resolving the contradiction between prediction accuracy and diagnostic complexity.
Solution Approach 2:
The patent introduces wound fluid as an intermediary medium between the wound tissue and the diagnostic system. Instead of directly analyzing complex tissue samples, the system uses metabolites in the wound fluid as proxies that reflect tissue health status, simplifying the diagnostic process while maintaining high prediction accuracy for healing outcomes.
2Loss of time
If standard care therapy is used for chronic wounds, then treatment approach remains simple, but time for amputation increases due to delayed intervention
Solution Approach 1:
The patent enables preliminary identification of wounds at risk for non-healing by detecting metabolite profiles before standard care fails. The biomarker system can identify refractory wounds early in the course of treatment, allowing clinicians to switch to advanced therapies before amputation becomes necessary, thus reducing time loss while maintaining reliable prediction.
Solution Approach 2:
The patent establishes a feedback mechanism where wound fluid metabolite analysis continuously monitors wound healing status. This feedback loop provides real-time information about wound response to treatment, enabling dynamic adjustment of care strategies and timely intervention to prevent amputation, thereby reducing time loss while improving prediction reliability.
3Reliability
If advanced therapies are applied early to non-healing wounds, then amputation risk is reduced, but treatment decision accuracy deteriorates without objective biomarkers
Solution Approach 1:
The patent replaces subjective clinical assessment mechanisms with objective biochemical measurement. Instead of relying on visual inspection and clinical judgment, the system uses metabolite detection in wound fluid to objectively determine healing status, thereby improving treatment decision accuracy while maintaining efficient wound care through rapid, quantifiable biomarker data.
4Measurement precision
If wound fluid metabolite analysis is performed, then early wound identification accuracy is improved, but measurement complexity increases
Solution Approach 1:
The patent segments the complex wound fluid metabolite profile into specific categories (amino acids, carbohydrates, vitamins, nucleotides, xenobiotics, peptides) and focuses on detecting particular metabolites within each category. This segmentation approach simplifies the measurement process by targeting specific biomarkers rather than requiring comprehensive analysis of all possible metabolites, thereby reducing detection difficulty while maintaining high identification accuracy.
Data Source
AI summary
Disclosed herein are compositions and methods for rapid identification of wounds that are refractory to standard wound care.